Nicolas et al., 2007 - Google Patents
Bcl‐2 overexpression delays caspase‐3 activation and rescues cerebellar degeneration in prion‐deficient mice that overexpress amino‐terminally truncated prionNicolas et al., 2007
View PDF- Document ID
- 1782874591641171312
- Author
- Nicolas O
- Gavín R
- Braun N
- Ureña J
- Fontana X
- Soriano E
- Aguzzi A
- Del Rio J
- Publication year
- Publication venue
- The FASEB Journal
External Links
Snippet
Prnp knockout mice that overexpress an amino‐truncated form of PrPc (ΔPrP) are ataxic and display cerebellar cell loss and premature death. Studies on the molecular and intracellular events that trigger cell death in these mutants may contribute to elucidate the functions of …
- 108060000885 BCL2 0 title abstract description 102
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hur | γ-Secretase in Alzheimer’s disease | |
| Hetz et al. | Caspase‐12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein | |
| Stroo et al. | Cellular regulation of amyloid formation in aging and disease | |
| Hayashi et al. | A seed for Alzheimer amyloid in the brain | |
| Wahrle et al. | Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease | |
| Alvarez et al. | Lithium protects cultured neurons against β-amyloid-induced neurodegeneration | |
| Li et al. | Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau | |
| Roucou et al. | Neuroprotective functions of prion protein | |
| Mizuno et al. | Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity | |
| Martin et al. | α‐Synuclein oligomers oppose long‐term potentiation and impair memory through a calcineurin‐dependent mechanism: relevance to human synucleopathic diseases | |
| Nie et al. | Dendrobium nobile Lindl. alkaloids decreases the level of intracellular β-amyloid by improving impaired autolysosomal proteolysis in APP/PS1 mice | |
| Zhao et al. | Mfn2 protects dopaminergic neurons exposed to paraquat both in vitro and in vivo: implications for idiopathic Parkinson's disease | |
| Nicolas et al. | Bcl‐2 overexpression delays caspase‐3 activation and rescues cerebellar degeneration in prion‐deficient mice that overexpress amino‐terminally truncated prion | |
| Yan et al. | TDP-43 causes differential pathology in neuronal versus glial cells in the mouse brain | |
| Ding et al. | Indirubin-3'-monoxime rescues spatial memory deficits and attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer's disease | |
| Manassero et al. | Beta‐amyloid 1‐42 monomers, but not oligomers, produce PHF‐like conformation of Tau protein | |
| Wang et al. | Death receptor 6 and caspase-6 regulate prion peptide-induced axonal degeneration in rat spinal neurons | |
| Li et al. | N-terminally deleted forms of the prion protein activate both Bax-dependent and Bax-independent neurotoxic pathways | |
| Song et al. | REST alleviates neurotoxic prion peptide-induced synaptic abnormalities, neurofibrillary degeneration and neuronal death partially via LRP6-mediated Wnt-β-catenin signaling | |
| Tian et al. | APP lysine 612 lactylation ameliorates amyloid pathology and memory decline in Alzheimer’s disease | |
| Piedrahita et al. | β-Secretase 1’s targeting reduces hyperphosphorilated tau, implying autophagy actors in 3xTg-AD mice | |
| Zhao et al. | Hereditary spastic paraplegia-associated mutations in the NIPA1 gene and its Caenorhabditis elegans homolog trigger neural degeneration in vitro and in vivo through a gain-of-function mechanism | |
| Zhou et al. | Polyphyllin I attenuates cognitive impairments and reduces AD‐like pathology through CIP2A‐PP2A signaling pathway in 3XTg‐AD mice | |
| Kimura et al. | Dynein dysfunction reproduces age-dependent retromer deficiency: concomitant disruption of retrograde trafficking is required for alteration in β-amyloid precursor protein metabolism | |
| Mansuy et al. | Deletion of plasma Phospholipid Transfer Protein (PLTP) increases microglial phagocytosis and reduces cerebral amyloid-β deposition in the J20 mouse model of Alzheimer's disease |